Brian McNamara

Brian McNamara has led Haleon as CEO since its landmark demerger from GSK in July 2022 — one of the largest European listings in a decade. Haleon was created by combining GSK's consumer healthcare business with the Pfizer consumer healthcare portfolio (acquired in 2019), resulting in the world's largest pure-play consumer health company with annual revenues exceeding £11 billion. Haleon's portfolio includes some of the most recognized healthcare brands globally: Sensodyne and parodontax (oral health — the largest category), Advil and Panadol (pain relief), Centrum and Caltrate (vitamins, minerals & supplements), Voltaren (topical pain), Theraflu and Otrivin (respiratory). The company holds #1 or #2 market positions in the majority of its categories. McNamara's strategy focuses on premiumization (driving consumers toward higher-value products), geographic expansion in emerging markets, and innovation within existing brands rather than acquisitions. The consumer health sector benefits from aging demographics, self-care trends, and the shift of prescription products to over-the-counter status. Key stock drivers include organic revenue growth, pricing power versus private label competition, emerging market penetration, input cost inflation, and the sustainability of consumer health spending in a cost-of-living environment.